Scinai Immunotherapeutics Ltd. (SCNI) Balance Sheet
SCNI balance sheet, 2025
December 31, 2025 · U.S. dollars$11.6M assets = $3.5M liabilities + $8.1M equity
Both columns are drawn to the same scale: what SCNI owns equals what it owes plus shareholders’ equity. Hover a block for its value.
SCNI financial health
Descriptive bands, not a rating. Fiscal 2025.
SCNI balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $7.8M2016 | $11.6M2025 | +4.5%/yr | |
| Total liabilities | $1.2M2016 | $3.5M2025 | +13.1%/yr | |
| Shareholders’ equity | $6.6M2016 | $8.1M2025 | +2.2%/yr | |
| Cash & short-term investments | $6.6M2016 | $1.7M2025 | −14.2%/yr | |
| Total debt | $25.2M2018 | $2.3M2025 | −29.1%/yr | |
| Net cash (debt) | −$4.9M2018 | −$606,0002025 | +$4.3M | |
| Working capital | $6.4M2016 | $469,0002025 | −$6.0M | |
| Current ratio | 19.012016 | 1.302025 | −17.71 | |
| Debt / equity | 29.772021 | 0.282025 | −29.49 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
SCNI assets
SCNI liabilities and equity
SCNI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
SCNI balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $1.7M | $2.0M | $4.9M | $14.1M | $17.4M | $2.9M | $21.0M | $20.3M | $20.5M | $6.6M |
| Cash & equivalents | $1.7M | $2.0M | $4.9M | $14.1M | $17.4M | $2.9M | $21.0M | $20.3M | $20.5M | $4.1M |
| Short-term investments | — | — | — | — | — | — | — | — | — | $2.5M |
| Receivables | $168,000 | $217,000 | $366,000 | $110,000 | $325,151 | $71,216 | $349,000 | $256,226 | $3.2M | $764,000 |
| Inventory | $0 | $0 | −$366,000 | −$852,279 | −$240,848 | −$3.9M | $0 | $0 | $0 | $51,000 |
| Other current assets | $225,000 | $210,000 | $577,000 | $1.0M | $384,697 | $4.2M | $0 | $1,823 | $0 | $0 |
| Total current assets | $2.1M | $2.4M | $5.4M | $14.4M | $17.8M | $3.3M | $21.2M | $20.5M | $21.6M | $6.8M |
| Property, plant & equipment (net) | $9.6M | $11.1M | $12.0M | $12.7M | $14.2M | $14.3M | $12.2M | $7.6M | $1.6M | $374,532 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $147,165 | $150,157 | $197,883 | $252,903 | $656,147 |
| Total assets | $11.6M | $13.4M | $17.5M | $27.1M | $32.0M | $17.7M | $33.5M | $28.3M | $23.5M | $7.8M |
| Liabilities | ||||||||||
| Accounts payable | $407,000 | $376,000 | $535,000 | $716,000 | $999,000 | $581,189 | $4.9M | $5.5M | $1.8M | $178,052 |
| Short-term debt | $329,000 | $424,000 | $396,000 | $382,000 | $623,361 | $19.0M | $200,967 | — | — | — |
| Deferred revenue | $90,000 | $225,000 | — | — | — | — | — | — | — | — |
| Total current liabilities | $1.6M | $1.8M | $1.8M | $2.3M | $2.4M | $20.0M | $5.5M | $5.8M | $2.0M | $356,883 |
| Long-term debt | $294,000 | $260,000 | $19.4M | $20.1M | $63.3M | $0 | $123.8M | $0 | $0 | $0 |
| Lease obligations | $2.0M | $1.8M | $1.2M | $1.5M | $6.5M | $2.1M | $7.5M | — | — | — |
| Other long-term liabilities | $1.6M | $1.4M | $893,000 | $6.4M | $0 | $2.3M | $0 | $30.8M | $5.3M | $809,541 |
| Total liabilities | $3.5M | $3.5M | $22.0M | $28.8M | $31.1M | $22.2M | $52.4M | $36.6M | $7.3M | $1.2M |
| Shareholders' equity | ||||||||||
| Retained earnings (deficit) | −$125.8M | −$117.5M | −$122.3M | −$115.8M | −$110.0M | −$101.1M | −$92.8M | −$56.5M | −$35.5M | −$23.1M |
| Accumulated other comprehensive income | −$1.7M | −$1.7M | −$1.7M | −$2.0M | −$2.1M | $0 | — | $0 | — | $374,013 |
| Total shareholders' equity | $8.1M | $10.0M | −$4.6M | −$1.8M | $982,000 | −$4.5M | −$18.8M | −$8.3M | $16.2M | $6.6M |
| Key figures | ||||||||||
| Total debt | $2.3M | $2.1M | $20.6M | $21.5M | $29.2M | $20.9M | $38.0M | $25.2M | — | — |
| Net cash (debt) | −$606,000 | −$122,000 | −$15.7M | −$7.5M | −$11.9M | −$18.0M | −$17.0M | −$4.9M | — | — |
| Working capital | $469,000 | $585,000 | $3.7M | $12.0M | $15.4M | −$16.7M | $15.7M | $14.7M | $19.7M | $6.4M |
| Tangible book value | $8.1M | $10.0M | −$4.6M | −$1.8M | $982,000 | −$4.5M | −$18.8M | −$8.3M | $16.2M | $6.6M |
| Current ratio | 1.30 | 1.32 | 3.06 | 6.15 | 7.30 | 0.17 | 3.86 | 3.53 | 10.94 | 19.01 |
| Quick ratio | 1.15 | 1.21 | 2.94 | 6.07 | 7.24 | 0.15 | 3.89 | 3.52 | 11.97 | 20.56 |
| Debt / equity | 0.28 | 0.21 | — | — | 29.77 | — | — | — | — | — |
| Equity / assets | 69.7% | 74.2% | −26.2% | −6.5% | 3.1% | −25.6% | −56.2% | −29.5% | 68.9% | 85.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $2.9M | $3.1M | $1.7M | $1.7M | $989,000 | $989,000 | $2.0M | $1.0M | $3.1M | $4.8M | $4.9M | $6.4M |
| Cash & equivalents | $2.9M | $3.1M | $1.7M | $1.7M | $989,000 | $989,000 | $2.0M | $1.0M | $3.1M | $4.8M | $4.9M | $6.4M |
| Short-term investments | — | — | — | — | — | — | — | — | $138,010 | — | — | — |
| Receivables | $73,999 | $150,000 | $73,000 | $73,000 | $139,000 | $139,000 | $83,000 | $448,000 | $119,000 | $288,000 | $366,000 | $228,000 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$328,000 | $0 | −$1.4M | −$1.9M | −$1.2M |
| Other current assets | $560,996 | $350,006 | $320,000 | $319,999 | $378,000 | $378,000 | $344,000 | $465,000 | $462,000 | $1.6M | $2.1M | $1.3M |
| Total current assets | $3.5M | $3.6M | $2.1M | $2.1M | $1.5M | $1.5M | $2.4M | $1.6M | $3.7M | $5.3M | $5.4M | $6.7M |
| Property, plant & equipment (net) | $13.7M | $14.0M | $9.6M | $9.6M | $10.3M | $10.3M | $11.1M | $10.6M | $11.2M | $11.8M | $12.0M | $11.9M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1 | $0 | $0 | $1 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $17.2M | $17.6M | $11.6M | $11.6M | $11.8M | $11.8M | $13.4M | $12.3M | $14.9M | $17.1M | $17.5M | $18.6M |
| Liabilities | ||||||||||||
| Accounts payable | $843,993 | $779,009 | $407,000 | $407,000 | $659,000 | $659,000 | $376,000 | $430,000 | $658,000 | $928,000 | $535,000 | $546,000 |
| Short-term debt | $368,997 | $354,004 | — | $329,000 | $497,000 | $497,000 | — | $364,000 | $364,000 | $387,000 | $396,000 | $382,000 |
| Deferred revenue | — | $90,000 | — | — | — | $225,000 | — | — | — | — | — | — |
| Total current liabilities | $2.2M | $2.7M | $1.6M | $1.6M | $2.1M | $2.1M | $1.8M | $1.4M | $1.7M | $1.9M | $1.8M | $1.5M |
| Long-term debt | $285,000 | $287,000 | $294,000 | $0 | $293,000 | $0 | $260,000 | $280,000 | $19.8M | $19.5M | $19.4M | $18.6M |
| Lease obligations | $3.3M | $3.2M | $2.0M | — | $2.1M | — | $1.8M | $947,000 | $1.0M | $1.1M | $1.2M | $1.2M |
| Other long-term liabilities | $2.9M | $2.9M | $1.6M | $1.9M | $1.6M | $1.9M | $1.4M | $586,000 | $643,000 | $732,000 | $893,000 | $1.1M |
| Total liabilities | $5.4M | $5.8M | $3.5M | $3.5M | $4.0M | $4.0M | $3.5M | $2.3M | $22.1M | $22.2M | $22.0M | $21.3M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | — | — | — | — | — | — | — | $5.6M | — | — | — | — |
| Retained earnings (deficit) | −$124.3M | −$122.3M | −$125.8M | −$125.8M | −$121.7M | −$121.7M | −$117.5M | −$115.3M | −$126.8M | −$124.5M | −$122.3M | −$120.0M |
| Accumulated other comprehensive income | −$2.1M | −$1.7M | — | −$1.7M | −$1.7M | −$1.7M | — | −$1.7M | −$1.7M | −$1.7M | −$1.7M | −$1.7M |
| Total shareholders' equity | $11.7M | $11.8M | $8.1M | $8.1M | $7.9M | $7.9M | $10.0M | $10.0M | −$7.3M | −$5.1M | −$4.6M | −$2.7M |
| Key figures | ||||||||||||
| Total debt | $3.6M | $3.5M | $294,000 | $2.3M | $2.4M | $2.4M | $260,000 | $1.2M | $20.8M | $20.6M | $20.6M | $19.8M |
| Net cash (debt) | −$726,994 | −$382,005 | $1.4M | −$606,000 | −$1.4M | −$1.4M | $1.7M | −$195,000 | −$17.7M | −$15.8M | −$15.7M | −$13.4M |
| Working capital | $1.3M | $929,011 | $469,000 | $468,999 | −$614,000 | −$614,000 | $585,000 | $225,000 | $2.0M | $3.3M | $3.7M | $5.2M |
| Tangible book value | $11.7M | $11.8M | $8.1M | $8.1M | $7.9M | $7.9M | $10.0M | $10.0M | −$7.3M | −$5.1M | −$4.6M | −$2.7M |
| Current ratio | 1.56 | 1.35 | 1.30 | 1.30 | 0.71 | 0.71 | 1.32 | 1.16 | 2.19 | 2.73 | 3.06 | 4.36 |
| Quick ratio | 1.31 | 1.22 | 1.09 | 1.09 | 0.53 | 0.53 | 1.13 | 1.06 | 1.91 | 2.66 | 2.94 | 4.28 |
| Debt / equity | 0.31 | 0.30 | 0.04 | 0.28 | 0.30 | 0.30 | 0.03 | 0.12 | — | — | — | — |
| Equity / assets | 68.3% | 66.9% | 69.7% | 69.7% | 66.4% | 66.4% | 74.2% | 81.6% | −49.0% | −30.0% | −26.2% | −14.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed April 1, 2026); data from EODHD.
SCNI financial position
At the end of fiscal 2025 (December 31, 2025), Scinai Immunotherapeutics had total assets of $11.6 million (down 13.5% from a year earlier), total liabilities of $3.5 million and shareholders' equity of $8.1 million. It held $1.7 million in cash and short-term investments against $2.3 million of debt, net debt of $0.6 million. Its current ratio was 1.30. In the latest quarter (ended June 30, 2026) total assets were $17.2 million and equity $11.7 million.
Related: SCNI income statement, SCNI cash flow statement, SCNI key metrics. See the SCNI stock overview for the latest quote and news.
SCNI balance sheet FAQ
What are Scinai Immunotherapeutics's total assets?
Scinai Immunotherapeutics reported total assets of $11.6 million at the end of fiscal 2025 (December 31, 2025), compared with $13.4 million a year earlier.
How much debt does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics had $2.3 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.28.
How much cash does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics held $1.7 million in cash and short-term investments at the end of fiscal 2025; with $2.3 million of debt that is net debt of $0.6 million.
What is Scinai Immunotherapeutics's book value?
Scinai Immunotherapeutics's shareholders' equity (book value) was $8.1 million at the end of fiscal 2025.
What is Scinai Immunotherapeutics's current ratio?
Scinai Immunotherapeutics had current assets of $2.1 million and current liabilities of $1.6 million, a current ratio of 1.30 (it can cover its short-term obligations).